# A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

> **NCT03887455** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eisai Inc.** · enrollment: 1906 (actual)

## Conditions studied

- Early Alzheimer's Disease

## Interventions

- **DRUG:** Lecanemab IV
- **DRUG:** Placebo
- **DRUG:** Lecanemab SC

## Key facts

- **NCT ID:** NCT03887455
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-27
- **Primary completion:** 2029-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 1906 (ACTUAL)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03887455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03887455, "A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03887455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*